Login to Your Account

Redhill to Start Phase III of Antibiotic Therapy in Crohn's

By Cormac Sheridan
Staff Writer

Wednesday, August 21, 2013
The controversial theory that infection with Mycobacterium avium subspecies paratuberculosis (MAP) is a causative agent in Crohn's disease is about to receive its biggest test yet, as Redhill Biopharma Ltd. initiates a Phase III program involving RHB-104, an antibiotic treatment, in some 600 patients.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription